Company / Capital Expenditures
Charles River Laboratories Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$219.2M
FY2025
5-year range
$140.5M / $233.0M
FY2021-FY2025
Trend
-5.9%
vs FY2024
Sector context
#40 of 150
Health Care
What the data says
At $219M, Charles River Laboratories's capital expenditures ranks #40 of 150 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $55M in FY2016 to $233M in FY2024.
Based on SEC 10-K filings.
$219M in FY2025 with a 5-year CAGR of +9.4%.
Declined from $229M to $219M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +9.6%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
#40 of 150 in Health CareTop 27% of 150This company $219.2M Sector average $271.1M
▼
-19.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, capital expenditures decreased 5.9% year-over-year.
- Ranks #40 out of 150 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $219.2M | -5.9% |
| FY2024 | $233.0M | +1.8% |
| FY2023 | $228.8M | +37.4% |
| FY2022 | $166.6M | +18.5% |
| FY2021 | $140.5M | +0.3% |
| FY2020 | $140.1M | +69.9% |
| FY2019 | $82.4M | -41.1% |
| FY2018 | $140.1M | +69.9% |
| FY2017 | $82.4M | +49.1% |
| FY2016 | $55.3M | +41.2% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026